Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients

Switch From Tacrolimus to Cyclosporine Microemulsion: Immunosuppressive Agents and Diabetes Management in Liver Transplant Recipients in Maintenance (DIALIVER)

The purpose of this study is to determine whether the switch from tacrolimus to cyclosporine microemulsion benefits post-transplant diabetes management (in terms of glycogenic control and insulin dosage) in stable liver transplant recipients.

Inclusion Criteria:

• At least 4 months post-transplant
• Patients in treatment with tacrolimus
• Post-transplant diabetes treated with insulin for at least one month

Exclusion Criteria

• Known hypersensitivity to cyclosporine microemulsion
• Investigational drug within 60 days before baseline or during the study
• Patients who cannot comply with the study requirements

Other protocol-defined exclusion criteria applied